Pharmacokinetics: an important factor in cancer treatment
This is SPARTAN! Apalutamide treatment for nmCRPC
IMMU-132 - a novel antibody-drug conjugate for the treatment of lung cancer
David Ross Camidge
Drugs with low response rates - should they always be offered to patients?
SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?